Overview

  • Dr. Rajendra Pol is a distinguished Hematologist in Baner Pune, who has done an MBBS from Pune university in the year 1999, He pursued MD in medicine from Pune university in the year 2002. He then relocated to the U.K and further pursued MRCP Medicine in the year 2006 from the Royal College of Physicians U.K. He then achieved FRCPathology-Hematology from Royal College of Physicians UK in the year 2014, Fellowship in Bone marrow Transplant in the years 2015-2016 satisfying the BSBMT U.K curriculum. Dr. Pol over 20 years has done over 1500 autologous transplants, 500 allogeneic transplants (donors from siblings, unrelated matched, umbilical cord, and haploidentical sources), and 55 CAR-T therapies.

  • He also achieved expertise in CAR-T therapy in Manchester for a year. He is an expert in interpreting Bone marrow Biopsies and correlating with MRD and molecular studies pre and post-allogeneic stem cell transplantation. His expertise is in Bone marrow / Haematopoetic stem cell transplantation, He does chemotherapies and has been known to treat a variety of bone marrow cancers like Leukemia, Lymphoma, Myeloma, Bone marrow failures, etc. He has been a Principal Investigator for the many UK and International trials like the MoTD trial for allogeneic stem cell transplant recipients, Sub-Investigator for allogeneic transplant, and CAR-T trials – Amadeus, COSI, MERC K, ALL-RIC, AUTO3, AUTO4, AUTO1, AUTO LT FU Sub-Investigator for Myeloid malignancies trials – AML18, AML19, PACE.

  • Field of Expertise

  • Haematology
  • Fellowship & Membership

  • British Society of Heamatology UK.
  • Member of Royal College of Pathologists UK.
  • Languages Spoken

  • English
  • Hindi
  • Marathi
  • Gujrati
  • Talks & Publications

  • Bone marrow fibrosis is not a predictor of overall survival in patients with multiple myeloma. R Pol, S Paneesha, N Chachlani, H Freeman, P Roberts, G Pratt, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Dexamethasone, Ifosfamide, Carboplatin and Etoposide (DICarE) with/out Rituximab is an effective regimen for elderly patients with high-grade lymphoma and poor cardiac function. S Paneesha, C Connor, R Pol, N Evans, N Chachlani, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Bone Marrow Fibrosis is a Negative Predictor for Osteolytic Lesions in Patients with Myeloma. S Paneesha, Raj Pol, N Chachlani, Guy Pratt, Peter Rose and Anton Borg. ‘American Society of Haematology’ Dec 2006. ‘British Journal of Haematology 2007’.
  • Image: ‘All that glitters is not gold’ (Thrombocytosis as a manifestation of renal cell carcinoma). S Paneesha, R Pol. N Chachlani, M Hughes, K Chen, P Rose and A Borg. Bloodmed 2006.
  • http://www.bloodmed.com/education/case1.asp?id=2065. The use of a faecal management device in gastrointestinal graft-versus-host disease.
  • S. Liebersbach, A. Wood, N. Davis, R. Pol, R. Mazumdar, G. Cook, M. Gilleece (Leeds, UK), 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, March 2010.
  • Image - Daunorubicin-induced Hyperpigmentation, published in British Journal of Haematology in Aug 2010. Raj Pol, Andrew Wright, Anita Hill.
  • Image – A man with anaemia and a change in personality, Blood, March 2014. Raj Pol, Martin Howard.
  • A Single centre experience in severe Veno-Occlusive Disease and Early Treatment with Defibrotide. Raj R. Pol, Nigel Russell, Emma Das-Gupta, Lynne Watson, Lisa Rachael, Jenny Byrne. Bone Marrow Transplantation advance online publication, 25 April 2016; doi:10.1038/bmt.2016.99. Also EBMT oral presentation in 2016.
  • Effective Treatment of Steroid and Therapy-R.

    Fellowship & Membership

  • British Society of Heamatology UK.
  • Member of Royal College of Pathologists UK.
  • Overview

  • Dr. Rajendra Pol is a distinguished Hematologist in Baner Pune, who has done an MBBS from Pune university in the year 1999, He pursued MD in medicine from Pune university in the year 2002. He then relocated to the U.K and further pursued MRCP Medicine in the year 2006 from the Royal College of Physicians U.K. He then achieved FRCPathology-Hematology from Royal College of Physicians UK in the year 2014, Fellowship in Bone marrow Transplant in the years 2015-2016 satisfying the BSBMT U.K curriculum. Dr. Pol over 20 years has done over 1500 autologous transplants, 500 allogeneic transplants (donors from siblings, unrelated matched, umbilical cord, and haploidentical sources), and 55 CAR-T therapies.

  • He also achieved expertise in CAR-T therapy in Manchester for a year. He is an expert in interpreting Bone marrow Biopsies and correlating with MRD and molecular studies pre and post-allogeneic stem cell transplantation. His expertise is in Bone marrow / Haematopoetic stem cell transplantation, He does chemotherapies and has been known to treat a variety of bone marrow cancers like Leukemia, Lymphoma, Myeloma, Bone marrow failures, etc. He has been a Principal Investigator for the many UK and International trials like the MoTD trial for allogeneic stem cell transplant recipients, Sub-Investigator for allogeneic transplant, and CAR-T trials – Amadeus, COSI, MERC K, ALL-RIC, AUTO3, AUTO4, AUTO1, AUTO LT FU Sub-Investigator for Myeloid malignancies trials – AML18, AML19, PACE.

  • Field of Expertise

  • Haematology
  • Languages Spoken

  • English
  • Hindi
  • Marathi
  • Gujrati
  • Talks & Publications

  • Bone marrow fibrosis is not a predictor of overall survival in patients with multiple myeloma. R Pol, S Paneesha, N Chachlani, H Freeman, P Roberts, G Pratt, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Dexamethasone, Ifosfamide, Carboplatin and Etoposide (DICarE) with/out Rituximab is an effective regimen for elderly patients with high-grade lymphoma and poor cardiac function. S Paneesha, C Connor, R Pol, N Evans, N Chachlani, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Bone Marrow Fibrosis is a Negative Predictor for Osteolytic Lesions in Patients with Myeloma. S Paneesha, Raj Pol, N Chachlani, Guy Pratt, Peter Rose and Anton Borg. ‘American Society of Haematology’ Dec 2006. ‘British Journal of Haematology 2007’.
  • Image: ‘All that glitters is not gold’ (Thrombocytosis as a manifestation of renal cell carcinoma). S Paneesha, R Pol. N Chachlani, M Hughes, K Chen, P Rose and A Borg. Bloodmed 2006.
  • http://www.bloodmed.com/education/case1.asp?id=2065. The use of a faecal management device in gastrointestinal graft-versus-host disease.
  • S. Liebersbach, A. Wood, N. Davis, R. Pol, R. Mazumdar, G. Cook, M. Gilleece (Leeds, UK), 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, March 2010.
  • Image - Daunorubicin-induced Hyperpigmentation, published in British Journal of Haematology in Aug 2010. Raj Pol, Andrew Wright, Anita Hill.
  • Image – A man with anaemia and a change in personality, Blood, March 2014. Raj Pol, Martin Howard.
  • A Single centre experience in severe Veno-Occlusive Disease and Early Treatment with Defibrotide. Raj R. Pol, Nigel Russell, Emma Das-Gupta, Lynne Watson, Lisa Rachael, Jenny Byrne. Bone Marrow Transplantation advance online publication, 25 April 2016; doi:10.1038/bmt.2016.99. Also EBMT oral presentation in 2016.
  • Effective Treatment of Steroid and Therapy-R.

    Languages Spoken

  • English
  • Hindi
  • Marathi
  • Gujrati
  • Overview

  • Dr. Rajendra Pol is a distinguished Hematologist in Baner Pune, who has done an MBBS from Pune university in the year 1999, He pursued MD in medicine from Pune university in the year 2002. He then relocated to the U.K and further pursued MRCP Medicine in the year 2006 from the Royal College of Physicians U.K. He then achieved FRCPathology-Hematology from Royal College of Physicians UK in the year 2014, Fellowship in Bone marrow Transplant in the years 2015-2016 satisfying the BSBMT U.K curriculum. Dr. Pol over 20 years has done over 1500 autologous transplants, 500 allogeneic transplants (donors from siblings, unrelated matched, umbilical cord, and haploidentical sources), and 55 CAR-T therapies.

  • He also achieved expertise in CAR-T therapy in Manchester for a year. He is an expert in interpreting Bone marrow Biopsies and correlating with MRD and molecular studies pre and post-allogeneic stem cell transplantation. His expertise is in Bone marrow / Haematopoetic stem cell transplantation, He does chemotherapies and has been known to treat a variety of bone marrow cancers like Leukemia, Lymphoma, Myeloma, Bone marrow failures, etc. He has been a Principal Investigator for the many UK and International trials like the MoTD trial for allogeneic stem cell transplant recipients, Sub-Investigator for allogeneic transplant, and CAR-T trials – Amadeus, COSI, MERC K, ALL-RIC, AUTO3, AUTO4, AUTO1, AUTO LT FU Sub-Investigator for Myeloid malignancies trials – AML18, AML19, PACE.

  • Fellowship & Membership

  • British Society of Heamatology UK.
  • Member of Royal College of Pathologists UK.
  • Field of Expertise

  • Haematology
  • Talks & Publications

  • Bone marrow fibrosis is not a predictor of overall survival in patients with multiple myeloma. R Pol, S Paneesha, N Chachlani, H Freeman, P Roberts, G Pratt, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Dexamethasone, Ifosfamide, Carboplatin and Etoposide (DICarE) with/out Rituximab is an effective regimen for elderly patients with high-grade lymphoma and poor cardiac function. S Paneesha, C Connor, R Pol, N Evans, N Chachlani, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Bone Marrow Fibrosis is a Negative Predictor for Osteolytic Lesions in Patients with Myeloma. S Paneesha, Raj Pol, N Chachlani, Guy Pratt, Peter Rose and Anton Borg. ‘American Society of Haematology’ Dec 2006. ‘British Journal of Haematology 2007’.
  • Image: ‘All that glitters is not gold’ (Thrombocytosis as a manifestation of renal cell carcinoma). S Paneesha, R Pol. N Chachlani, M Hughes, K Chen, P Rose and A Borg. Bloodmed 2006.
  • http://www.bloodmed.com/education/case1.asp?id=2065. The use of a faecal management device in gastrointestinal graft-versus-host disease.
  • S. Liebersbach, A. Wood, N. Davis, R. Pol, R. Mazumdar, G. Cook, M. Gilleece (Leeds, UK), 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, March 2010.
  • Image - Daunorubicin-induced Hyperpigmentation, published in British Journal of Haematology in Aug 2010. Raj Pol, Andrew Wright, Anita Hill.
  • Image – A man with anaemia and a change in personality, Blood, March 2014. Raj Pol, Martin Howard.
  • A Single centre experience in severe Veno-Occlusive Disease and Early Treatment with Defibrotide. Raj R. Pol, Nigel Russell, Emma Das-Gupta, Lynne Watson, Lisa Rachael, Jenny Byrne. Bone Marrow Transplantation advance online publication, 25 April 2016; doi:10.1038/bmt.2016.99. Also EBMT oral presentation in 2016.
  • Effective Treatment of Steroid and Therapy-R.

    Field of Expertise

  • Haematology
  • Fellowship & Membership

  • British Society of Heamatology UK.
  • Member of Royal College of Pathologists UK.
  • Languages Spoken

  • English
  • Hindi
  • Marathi
  • Gujrati
  • Talks & Publications

  • Bone marrow fibrosis is not a predictor of overall survival in patients with multiple myeloma. R Pol, S Paneesha, N Chachlani, H Freeman, P Roberts, G Pratt, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Dexamethasone, Ifosfamide, Carboplatin and Etoposide (DICarE) with/out Rituximab is an effective regimen for elderly patients with high-grade lymphoma and poor cardiac function. S Paneesha, C Connor, R Pol, N Evans, N Chachlani, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Bone Marrow Fibrosis is a Negative Predictor for Osteolytic Lesions in Patients with Myeloma. S Paneesha, Raj Pol, N Chachlani, Guy Pratt, Peter Rose and Anton Borg. ‘American Society of Haematology’ Dec 2006. ‘British Journal of Haematology 2007’.
  • Image: ‘All that glitters is not gold’ (Thrombocytosis as a manifestation of renal cell carcinoma). S Paneesha, R Pol. N Chachlani, M Hughes, K Chen, P Rose and A Borg. Bloodmed 2006.
  • http://www.bloodmed.com/education/case1.asp?id=2065. The use of a faecal management device in gastrointestinal graft-versus-host disease.
  • S. Liebersbach, A. Wood, N. Davis, R. Pol, R. Mazumdar, G. Cook, M. Gilleece (Leeds, UK), 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, March 2010.
  • Image - Daunorubicin-induced Hyperpigmentation, published in British Journal of Haematology in Aug 2010. Raj Pol, Andrew Wright, Anita Hill.
  • Image – A man with anaemia and a change in personality, Blood, March 2014. Raj Pol, Martin Howard.
  • A Single centre experience in severe Veno-Occlusive Disease and Early Treatment with Defibrotide. Raj R. Pol, Nigel Russell, Emma Das-Gupta, Lynne Watson, Lisa Rachael, Jenny Byrne. Bone Marrow Transplantation advance online publication, 25 April 2016; doi:10.1038/bmt.2016.99. Also EBMT oral presentation in 2016.
  • Effective Treatment of Steroid and Therapy-R.
  • Overview

  • Dr. Rajendra Pol is a distinguished Hematologist in Baner Pune, who has done an MBBS from Pune university in the year 1999, He pursued MD in medicine from Pune university in the year 2002. He then relocated to the U.K and further pursued MRCP Medicine in the year 2006 from the Royal College of Physicians U.K. He then achieved FRCPathology-Hematology from Royal College of Physicians UK in the year 2014, Fellowship in Bone marrow Transplant in the years 2015-2016 satisfying the BSBMT U.K curriculum. Dr. Pol over 20 years has done over 1500 autologous transplants, 500 allogeneic transplants (donors from siblings, unrelated matched, umbilical cord, and haploidentical sources), and 55 CAR-T therapies.

  • He also achieved expertise in CAR-T therapy in Manchester for a year. He is an expert in interpreting Bone marrow Biopsies and correlating with MRD and molecular studies pre and post-allogeneic stem cell transplantation. His expertise is in Bone marrow / Haematopoetic stem cell transplantation, He does chemotherapies and has been known to treat a variety of bone marrow cancers like Leukemia, Lymphoma, Myeloma, Bone marrow failures, etc. He has been a Principal Investigator for the many UK and International trials like the MoTD trial for allogeneic stem cell transplant recipients, Sub-Investigator for allogeneic transplant, and CAR-T trials – Amadeus, COSI, MERC K, ALL-RIC, AUTO3, AUTO4, AUTO1, AUTO LT FU Sub-Investigator for Myeloid malignancies trials – AML18, AML19, PACE.

    Talks & Publications

  • Bone marrow fibrosis is not a predictor of overall survival in patients with multiple myeloma. R Pol, S Paneesha, N Chachlani, H Freeman, P Roberts, G Pratt, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Dexamethasone, Ifosfamide, Carboplatin and Etoposide (DICarE) with/out Rituximab is an effective regimen for elderly patients with high-grade lymphoma and poor cardiac function. S Paneesha, C Connor, R Pol, N Evans, N Chachlani, P Rose and A Borg. British Journal of Haematology 2006, 108, 133, (Suppl. 1), 1-121 (Abstract).
  • Bone Marrow Fibrosis is a Negative Predictor for Osteolytic Lesions in Patients with Myeloma. S Paneesha, Raj Pol, N Chachlani, Guy Pratt, Peter Rose and Anton Borg. ‘American Society of Haematology’ Dec 2006. ‘British Journal of Haematology 2007’.
  • Image: ‘All that glitters is not gold’ (Thrombocytosis as a manifestation of renal cell carcinoma). S Paneesha, R Pol. N Chachlani, M Hughes, K Chen, P Rose and A Borg. Bloodmed 2006.
  • http://www.bloodmed.com/education/case1.asp?id=2065. The use of a faecal management device in gastrointestinal graft-versus-host disease.
  • S. Liebersbach, A. Wood, N. Davis, R. Pol, R. Mazumdar, G. Cook, M. Gilleece (Leeds, UK), 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, March 2010.
  • Image - Daunorubicin-induced Hyperpigmentation, published in British Journal of Haematology in Aug 2010. Raj Pol, Andrew Wright, Anita Hill.
  • Image – A man with anaemia and a change in personality, Blood, March 2014. Raj Pol, Martin Howard.
  • A Single centre experience in severe Veno-Occlusive Disease and Early Treatment with Defibrotide. Raj R. Pol, Nigel Russell, Emma Das-Gupta, Lynne Watson, Lisa Rachael, Jenny Byrne. Bone Marrow Transplantation advance online publication, 25 April 2016; doi:10.1038/bmt.2016.99. Also EBMT oral presentation in 2016.
  • Effective Treatment of Steroid and Therapy-R.
  • Overview

  • Dr. Rajendra Pol is a distinguished Hematologist in Baner Pune, who has done an MBBS from Pune university in the year 1999, He pursued MD in medicine from Pune university in the year 2002. He then relocated to the U.K and further pursued MRCP Medicine in the year 2006 from the Royal College of Physicians U.K. He then achieved FRCPathology-Hematology from Royal College of Physicians UK in the year 2014, Fellowship in Bone marrow Transplant in the years 2015-2016 satisfying the BSBMT U.K curriculum. Dr. Pol over 20 years has done over 1500 autologous transplants, 500 allogeneic transplants (donors from siblings, unrelated matched, umbilical cord, and haploidentical sources), and 55 CAR-T therapies.

  • He also achieved expertise in CAR-T therapy in Manchester for a year. He is an expert in interpreting Bone marrow Biopsies and correlating with MRD and molecular studies pre and post-allogeneic stem cell transplantation. His expertise is in Bone marrow / Haematopoetic stem cell transplantation, He does chemotherapies and has been known to treat a variety of bone marrow cancers like Leukemia, Lymphoma, Myeloma, Bone marrow failures, etc. He has been a Principal Investigator for the many UK and International trials like the MoTD trial for allogeneic stem cell transplant recipients, Sub-Investigator for allogeneic transplant, and CAR-T trials – Amadeus, COSI, MERC K, ALL-RIC, AUTO3, AUTO4, AUTO1, AUTO LT FU Sub-Investigator for Myeloid malignancies trials – AML18, AML19, PACE.

  • Fellowship & Membership

  • British Society of Heamatology UK.
  • Member of Royal College of Pathologists UK.
  • Field of Expertise

  • Haematology
  • Languages Spoken

  • English
  • Hindi
  • Marathi
  • Gujrati
Call Us